Innatera Nanosystems develops a human mucus model to replicate different mucus conditions, both normal and diseased, for microbiology research. Its product provides a 3D substrate that hosts bacteria, allowing the creation of infection-like environments in vitro. This enables high-throughput and reproducible testing of antibiotics and other bacteria-modulating drugs. Unlike traditional flat media, its mucus-based model aims to better mimic the human body so drug discovery can be more accurate and efficient. The company’s goal is to transform microbiology by offering realistic, scalable mucus environments that improve the discovery and testing of antibiotics.
Company Size
51-200
Company Stage
Series A
Total Funding
$29M
Headquarters
Rijswijk, Netherlands
Founded
2018
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?